Bank of America Resumes Coverage on Bristol-Myers (BMY) with a Neutral
More News related to BMY
- FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include 96-Week Data for Previously Untreated HIV-1 Infected Adult Patients
- Trading Outlook for Avanir Pharmaceuticals Inc. Issued by InvestorSoup.com
- ZymoGenetics (ZGEN) and Bristol-Myers (BMY) Present Phase 1b PEG-Interferon Data for HCV Treatment
- Semi-Annual Changes to the NASDAQ OMX CRD Global Sustainability 50 Index
- Trading Review for Cell Therapeutics Incorporated Issued by Beacon Equity
Bank of America resumes coverage on Bristol-Myers (NYSE: BMY) with a Neutral. Price target $22.
To see more analyst ratings on BMY Click Here.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical and nutritional products. The Company had two segments: Pharmaceuticals and Nutritionals.
Related Categories
New CoverageStocks Mentioned
+0.14Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
